高级搜索

小肠原发恶性肿瘤根治术后辅助化疗疗效分析

郭晓川, 张婷婷, 苏丹, 毛志远, 白莉

郭晓川, 张婷婷, 苏丹, 毛志远, 白莉. 小肠原发恶性肿瘤根治术后辅助化疗疗效分析[J]. 肿瘤防治研究, 2013, 40(07): 693-697. DOI: 10.3971/j.issn.1000-8578.2013.07.014
引用本文: 郭晓川, 张婷婷, 苏丹, 毛志远, 白莉. 小肠原发恶性肿瘤根治术后辅助化疗疗效分析[J]. 肿瘤防治研究, 2013, 40(07): 693-697. DOI: 10.3971/j.issn.1000-8578.2013.07.014
GUO Xiaochuan, ZHANG Tingting, SU Dan, MAO Zhiyuan, BAI Li. Clinical Analysis of Postoperative Adjuvant Chemotherapy of Small Intestine Primary Malignancies[J]. Cancer Research on Prevention and Treatment, 2013, 40(07): 693-697. DOI: 10.3971/j.issn.1000-8578.2013.07.014
Citation: GUO Xiaochuan, ZHANG Tingting, SU Dan, MAO Zhiyuan, BAI Li. Clinical Analysis of Postoperative Adjuvant Chemotherapy of Small Intestine Primary Malignancies[J]. Cancer Research on Prevention and Treatment, 2013, 40(07): 693-697. DOI: 10.3971/j.issn.1000-8578.2013.07.014

小肠原发恶性肿瘤根治术后辅助化疗疗效分析

详细信息
    作者简介:

    郭晓川(1987-),女,硕士在读,住院医师,主要从事胃肠道肿瘤方面的研究

    通讯作者:

    白莉,E-mail:bailinvshi@126.com

  • 中图分类号: R735.3+2

Clinical Analysis of Postoperative Adjuvant Chemotherapy of Small Intestine Primary Malignancies

  • 摘要: 目的 评价根治术后辅助化疗对小肠原发恶性肿瘤疗效的影响。 方法 回顾性分析解放军总医院2001年1月—2010年6月55例小肠原发恶性肿瘤根治术后患者的临床资料,主要终点观察指标是中位无疾病生存期,次要观察指标为1年、2年生存率,影响预后的因素。 结果 单纯手术组和术后辅助化疗组中位无疾病生存期(mDFS)(分别为15.0月、28.0月(P=0.035<0.05);1、2年无疾病生存率分别为61.1%、73.7%(P=0.351)和36.1%、56.0%(P=0.418);1、2年生存率分别为75.9%、100%(P=0.001)和68.0%、93.8%(P=0.025);肿瘤的浸润深度是影响患者预后的重要因素(P<0.05);而分化程度、临床分期、肿瘤大小及部位等对预后的影响没有统计学意义。 结论 根治术后辅助化疗具有能延长患者的无疾病生存时间的趋势,单纯手术组与术后辅助化疗组两组之间差异有统计学意义;肿瘤的浸润深度是影响预后的重要因素(P<0.05)。

     

    Abstract: Objective To evaluate the efficacy of postoperative adjuvant chemotherapy in patients with small intestine primary malignancies; Methods The clinical and follow-up date of 55 patients with small intestine primary malignancies who underwent surgery from January 2001 to June 2010 in our hospital were retrospectively analyzed. The primary end point was the median disease free survival rate and 1- and 2-year survival rates, affecting prognostics factors were evaluated. Results The median disease free survival time was 15.0 month for the chemotherapy group and 28.0 month for the surgery group.(P=0.035<0.05); the 1-year DFS was 61.1% and 73.7% respectively(P=0.351),the 2-year DFS was 36.1% and 56.0%,respectively(P=0.481);the 1-year survival rate was 75.9% and 100%,respectively(P=0.001);the 2-year survival rate was 68.0% and 93.8%,respectively(P=0.025).The depth of tumor was a predictor of poor prognosis;however,the differentiation degree, stage, size and place of tumor had no significance of prognosis. Conclusion Postoperative adjuvant chemotherapy may prolong the median disease free survival rate(P<0.05);both the surgery group and the postoperative adjuvant chemotherapy group has significant difference.The depth of tumor is a predictor of poor prognosis.

     

  • [1] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
    [2] The incidence of malignant tumor of Shanghai in 2005[J].Shanghai Yu Fang Yi Xue,2008,20(8):421-2. [2005年上海市恶性肿瘤发病率[J].上海预防医学,2008,20(8):421-2.]
    [3] Howe JR, Karnell LH, Menck HR, et al. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base,1985-1995[J]. Cancer,1999,86(12):2693-706.
    [4] Agrawal S, McCarron EC, Gibbs JF, et al.Surgical management and outcome in primary adenocarcinoma of the small bowel[J].Ann Surg Oncol,2007,14(8):2263-9.
    [5] Fishman PN, Pond GR, Moore MJ, et al.Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases[J]. Am J Clin Oncol,2006,29(3):225-31.
    [6] Dabaja BS, Suki D, Pro B, et al.Adenocarcinoma of the small bowel: presentation, prog-nostic factors, and outcome of 217 patients[J]. Cancer, 2004,101(3):518-26.
    [7] Sohn TA, Lillemoe KD, Cameron JL, et al.Adenocarcinoma of the duodenum: factors influencing long-term survival[J]. J Gastrointest Surg,1998,2(1):79-87.
    [8] Koo DH,Yun SC,Hong YS,et al.Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery[J].Oncology,2011,80(3-4):208-13.
    [9] Overman MJ.Recent advances in the management of adenocarcinoma of the small intestine[J].Gastrointest Cancer Res,2009,3(3):90-6.
    [10] Halfdanarson TR, McWilliams RR, Donohue JH, et al.A single-institution experience with 491 cases of small bowel adenocarcinoma[J].Am J Surg,2010,199(6):797-803.
    [11] Moon YW, Rha SY, Shin SJ, et al.Adenocarcinoma of the small bowel at a single Korean institute:management and prognosticators[J]. J Cancer Res Clin Oncol,2010,136(3):387-94.
    [12] Talamonti MS, Goetz LH, Rao S,et al.Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management[J]. Arch Surg,2002,137(5): 564-70.
    [13] Bakaeen FG,Murr MM,Sarr MG,et al.What prognosticfactors are important in duodenal adenocarcinoma[J].Arch Surg,2000,135(6):635-41.
    [14] Stefano Cecc hini,Camilo Correa-Gallego,Vikram Des phande,et al.Superior Prognostic Importance of Perineura l Invasion vs Lymph Node Involvement After Curative Resection of Duode nal Adenoca rcinoma[J]. J Gastrointest Surg,2012,16(1):113-20.
计量
  • 文章访问数:  2029
  • HTML全文浏览量:  23
  • PDF下载量:  406
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-08-05
  • 修回日期:  2012-10-09
  • 刊出日期:  2013-07-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭